MX2022012934A - Agente terapeutico para cancer de mama. - Google Patents

Agente terapeutico para cancer de mama.

Info

Publication number
MX2022012934A
MX2022012934A MX2022012934A MX2022012934A MX2022012934A MX 2022012934 A MX2022012934 A MX 2022012934A MX 2022012934 A MX2022012934 A MX 2022012934A MX 2022012934 A MX2022012934 A MX 2022012934A MX 2022012934 A MX2022012934 A MX 2022012934A
Authority
MX
Mexico
Prior art keywords
therapeutic agent
breast cancer
cancer therapeutic
antiestrogens
cdk
Prior art date
Application number
MX2022012934A
Other languages
English (en)
Inventor
Satoshi Kawano
Saori MIYANO
Kyoko NISHIBATA
Sayo FUKUSHIMA
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2022012934A publication Critical patent/MX2022012934A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona un agente terapéutico para tratar el cáncer de mama que ha desarrollado resistencia a la administración de inhibidores de CDK4/6 y antagonistas de estrógenos, conteniendo el agente 5-((2-(4-(1-(2-hidroxietil)piperidin-4-il)benzamida)piri din-4-il)oxi)-6-(2-metoxietoxi)-N-metil-1H-indol-1-carboxamida o una sal farmacológicamente aceptable de la misma.
MX2022012934A 2020-04-17 2021-04-15 Agente terapeutico para cancer de mama. MX2022012934A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020074386 2020-04-17
PCT/JP2021/015546 WO2021210636A1 (ja) 2020-04-17 2021-04-15 乳がん治療剤

Publications (1)

Publication Number Publication Date
MX2022012934A true MX2022012934A (es) 2022-11-08

Family

ID=78084563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012934A MX2022012934A (es) 2020-04-17 2021-04-15 Agente terapeutico para cancer de mama.

Country Status (10)

Country Link
US (1) US20230149381A1 (es)
EP (1) EP4122465A4 (es)
JP (1) JPWO2021210636A1 (es)
KR (1) KR20230004595A (es)
CN (1) CN115397415A (es)
AU (1) AU2021255084A1 (es)
BR (1) BR112022020786A2 (es)
CA (1) CA3180128A1 (es)
MX (1) MX2022012934A (es)
WO (1) WO2021210636A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4151212A4 (en) * 2020-07-31 2024-04-10 Eisai R&D Management Co., Ltd. THERAPEUTIC AGENT AGAINST BREAST CANCER

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR094812A1 (es) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
JP2014235614A (ja) 2013-06-03 2014-12-15 株式会社ゼネット 総合学習支援ネットワークシステム及び総合学習支援方法
ES2914072T3 (es) 2014-08-18 2022-06-07 Eisai R&D Man Co Ltd Sal de derivado de piridina monocíclico y su cristal
CN114984013A (zh) 2015-03-25 2022-09-02 国立癌症研究中心 胆管癌治疗剂
CN115177619A (zh) * 2015-12-17 2022-10-14 卫材R&D管理有限公司 用于乳腺癌的治疗剂
JP2017217935A (ja) 2016-06-03 2017-12-14 株式会社東海理化電機製作所 ステアリングスイッチ装置
JP2018022750A (ja) 2016-08-02 2018-02-08 太陽誘電株式会社 積層セラミックコンデンサ
US20190192522A1 (en) * 2016-09-08 2019-06-27 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors
CN111712245A (zh) 2018-03-28 2020-09-25 卫材R&D管理有限公司 用于肝细胞癌的治疗剂

Also Published As

Publication number Publication date
WO2021210636A1 (ja) 2021-10-21
EP4122465A4 (en) 2024-03-20
EP4122465A1 (en) 2023-01-25
JPWO2021210636A1 (es) 2021-10-21
BR112022020786A2 (pt) 2022-11-29
CN115397415A (zh) 2022-11-25
AU2021255084A1 (en) 2022-12-08
CA3180128A1 (en) 2021-10-21
KR20230004595A (ko) 2023-01-06
US20230149381A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
US20200323852A1 (en) Compounds And Compositions As Protein Kinase Inhibitors
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
NZ603231A (en) Cgrp receptor antagonist and its use for treating conditions such as migraine, neuropathic pain and proliferative diseases
MX2021013817A (es) Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
SE0202462D0 (sv) Novel use
NZ627750A (en) Carbamate compounds and of making and using same
CA2995675C (en) Heteroaryl compounds and their use as therapeutic drugs
MX2023014028A (es) Inhibidores de cinasa de punto de control 1 (chk1) y usos de los mismos.
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
AR112284A1 (es) Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
MX2022012934A (es) Agente terapeutico para cancer de mama.
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
PE20210417A1 (es) Nuevo derivado de amina heterociclico y composicion farmaceutica que lo comprende
MX2022009059A (es) Compuestos heterociclicos novedosos utiles como inhibidores selectivos de aurora a.
MX2020008610A (es) Agente terapeutico para carcinoma hepatocelular.
RU2018119102A (ru) Терапевтическое средство для лечения рака молочной железы
ATE473212T1 (de) Hiv-inhibierende 2-(4-cyanophenyl)-6- hydroxylaminopyrimidine
MX2021013942A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.
MX2023010268A (es) Formas salinas novedosas de un inhibidor de cyp11a1 de estructura 4h-piran-4-ona.
IS2712B (is) Notkun týrósínkínasatálma til að meðhöndla sykursýki
PE20070323A1 (es) Composicion que comprende 4-(2,4-dicloro-5-metoxi-fenilamino)-6-metoxi-7-[3-(4-metil-piperazin-1-il)-propoxi]-quinolin-3-carbonitrilo como inhibidor de tirosina quinasa
MX2023010322A (es) Método para tratar una afección usando una dosis terapéuticamente efectiva del inhibidor de malt1 jnj-67856633 (1-(1-(1- oxo-1,2-dihidroisoquinolina-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piriidin-4-il)-1h-pirazol-4-carboxamida).
CR20230162A (es) Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos
MX2023000060A (es) Agente terapeutico para cancer de mama.